Topic Collection Search
Allergy and immunology
Complementary medicine and alternative therapies
Critical care / intensive care
Dentistry / oral medicine
Geriatric medicine / aging
Haematology / blood transfusion
History of medicine
Legal and forensic medicine
Nutrition and metabolism
Obstetrics and gynaecology
Occupational and environmental medicine
Organisation of health care
Otolaryngology / head and neck surgery
Pharmacology and therapeutics
Primary care, family medicine
Psychiatry and psychotherapy
Quality of care
Statistics and research methods
Early advance care planning in amyotrophic lateral sclerosis patients: results of a systematic intervention by a palliative care team in a multidisciplinary management programme – a 4-year cohort study
Early initiation of advance care planning is feasible in most ALS patients during a routine consultation, and relevant treatment issues can be discussed. All ALS patients should be offered the opportunity to write advance directives as completion was not associated with disease severity.
Continuous versus routine EEG in critically ill adults: reimbursement analysis of a randomised trial
In a Swiss Diagnosis Related Groups billing system applied to critically ill adults, reimbursement largely depends on duration of acute hospital stay, whereas continuous EEG and lack of seizure/ status epilepticus detection also contribute to the bill. This differs from the USA, where charges are directly increased by continuous EEG.
Characterisation of advanced Parkinson’s disease: OBSERVE-PD observational study – results of the Swiss subgroup
Currently, the characterisation of advanced Parkinson’s disease does not follow standardised diagnostic criteria, which complicates the evaluation of ongoing care and treatment strategies, such as eligibility for device-aided treatment. Therefore, this study aimed to determine the proportion of advanced and non-advanced Parkinson’s disease patients treated at specialised movement disorder centres in Switzerland, to compare clinical characteristics and to assess eligibility for and use of device-aided treatment.
These are the Swiss Amyloidosis Network recommendations which focus on diagnostic work-up and treatment of AL-amyloidosis. One aim of this meeting was to establish a consensus guideline regarding the diagnostic work-up and the treatment recommendations for systemic amyloidosis tailored to the Swiss health care system.
A Swiss panel of experts met for the Dementia Summit in Brunnen, Switzerland, to discuss the latest scientific findings on basic and clinical research, as well as practical and political approaches to the challenges of dementia disorders in Switzerland. Here, they present the conference summary.
Immune checkpoint inhibitor therapy-associated encephalitis: a case series and review of the literature
Encephalitis should be suspected in patients treated with immune checkpoint inhibitors who present with rapidly evolving confusion. Blood tests, CSF analysis, cerebral MRI and an EEG should be performed. Therapy with intravenous corticosteroids is recommended. Steroid unresponsiveness is rare and should lead to a review of the diagnosis. Alternative treatment options are IVIG, plasma exchange therapy and rituximab.
Multisystem inflammatory syndrome with refractory cardiogenic shock due to acute myocarditis and mononeuritis multiplex after SARS-CoV-2 infection in an adult
Multisystem inflammatory syndrome associated with SARS-CoV-2 can occur in adults. The clinical presentation can include severe organ damage with features of incomplete or complete Kawasaki disease, including coronary aneurysm, as well as myocarditis-associated cardiogenic shock and also mononeuritis multiplex.
Homonymous visual field defects in patients with multiple sclerosis: results of computerised perimetry and optical coherence tomography
Homonymous visual field defects can be the first manifestation of multiple sclerosis and have a relatively good prognosis. The incidence of HVFD in multiple sclerosis is unknown, as it is probably underdiagnosed.
The placebo effect represents an elegant model to understand how the brain works. It is worth knowing that there is not a single but many placebo effects, with different mechanisms across different systems, medical conditions and therapeutic interventions.